Small Molecule Reversible Inhibitors of Bruton's Tyrosine Kinase (BTK): Structure-Activity Relationships Leading to the Identification of 7-(2-Hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide (BMS-935177)

被引：42

作者：

De Lucca, George V. ^{[1
]}

Shi, Qing ^{[1
]}

Liu, Qingjie ^{[1
]}

Batt, Douglas G. ^{[1
]}

Bertrand, Myra Beaudoin ^{[1
]}

Rampulla, Rick ^{[1
]}

Mathur, Arvind ^{[1
]}

Discenza, Lorell ^{[4
]}

D'Arienzo, Celia ^{[4
]}

Dai, Jun ^{[4
]}

Obermeier, Mary ^{[4
]}

Vickery, Rodney ^{[4
]}

Zhang, Yingru ^{[4
]}

Yang, Zheng ^{[4
]}

Marathe, Punit ^{[4
]}

Tebben, Andrew J. ^{[3
]}

Muckelbauer, Jodi K. ^{[3
]}

Chang, ChiehYing J. ^{[3
]}

Zhang, Huiping ^{[1
]}

Gillooly, Kathleen ^{[2
]}

Taylor, Tracy ^{[2
]}

Pattoli, Mark A. ^{[2
]}

Skala, Stacey ^{[2
]}

Kukral, Daniel W. ^{[5
]}

McIntyre, Kim W. ^{[2
]}

Salter-Cid, Luisa ^{[2
]}

Fura, Aberra ^{[4
]}

Burke, James R. ^{[2
]}

Banish, Joel C. ^{[1
]}

Carter, Percy H. ^{[1
]}

Tino, Joseph A. ^{[1
]}

机构：

[1] Bristol Myers Squibb Res & Dev, Immunosci Discovery Chem, POB 4000, Princeton, NJ 08543 USA

[2] Bristol Myers Squibb Res & Dev, Immunosci Discovery Biol, POB 4000, Princeton, NJ 08543 USA

[3] Bristol Myers Squibb Res & Dev, Mol Struct & Design, Mol Discovery Technol, POB 4000, Princeton, NJ 08543 USA

[4] Bristol Myers Squibb Res & Dev, Metab & Pharmacokinet Dept, Pharmaceut Candidate Optimizat, POB 4000, Princeton, NJ 08543 USA

[5] Bristol Myers Squibb Res & Dev, ECTR CTTO, Dept Imaging, POB 4000, Princeton, NJ 08543 USA

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2016年 / 59卷 / 17期

关键词：

BIOANALYTICAL PLATFORM; RHEUMATOID-ARTHRITIS; METABOLIC STABILITY; AUTOIMMUNE-DISEASES; CELL ACTIVATION; B-CELLS; DISCOVERY; POTENT; IMMUNODEFICIENCY; MICE;

D O I：

10.1021/acs.jmedchem.6b00722

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Bruton's tyrosine,kinase (BTK) belongs to the TEC family of nonreceptor tyrosine kinases and plays a critical role in multiple cell types responsible for numerous auto-immune diseases. This article will detail the structure-activity relationships (SARs) leading to a novel second generation series of potent and, selective reversible carbazole inhibitors of BTK. With an excellent pharmacokinetic profile as well as demonstrated in vivo activity and an acceptable safety profile, 7-(2-hydroxypropan-2-yl)-4-[2-methyl-3-(4-oXo-3,4-dihydroquinazdlin-3-yl)phenyl]-9H-carbazole-1-carboxarnide 6 (BMS-935177) was selected:to advance into clinical development.

引用

页码：7915 / 7935

页数：21

共 24 条

[21] Design of new potent and selective secretory phospholipase A2 inhibitors. 6-Synthesis, structure-activity relationships and molecular modelling of 1-substituted-4-[4,5-dihydro-1,2,4-(4H)-oxadiazol-5-one-3-yl(methyl)]-functionalized aryl piperazin/one/dione derivatives
Meddad-Belhabich, Nadia
Aoun, Darina
Djimde, Atime
Redeuilh, Catherine
Dive, Georges
Massicot, France
Chau, Francois
Heymans, Francoise
Lamouri, Aazdine
BIOORGANIC & MEDICINAL CHEMISTRY, 2010, 18 (10) : 3588 - 3600
[22] Optimization of Activity, Selectivity, and Liability Profiles in 5-0xopyrrolopyridine DPP4 Inhibitors Leading to Clinical Candidate (Sa)-2-(3-(Aminomethyl)-4-(2,4-dichloropheny1)-2-methyl5-oxo-5H-pyrrolo(3,4-b)pyridin-6(7H)-y1)-N,N-dimethylacetamide (BMS-767778)
Devasthale, Pratik
Wang, Ying
Wang, Wei
Fevig, John
Feng, JianXin
Wang, Aiying
Harrity, Tom
Egan, Don
Morgan, Nathan
Cap, Michael
Fura, Aberra
Klei, Herbert E.
Kish, Kevin
Weigelt, Carolyn
Sun, Lucy
Levesque, Paul
Moulin, Frederic
Li, Yi-Xin
Zahler, Robert
Kirby, Mark S.
Hamann, Lawrence G.
JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (18) : 7343 - 7357
[23] Structure-Activity Relationship Studies Leading to the Identification of (2E)-3-[1-[2,4-Dichlorophenyl)methyl]-5-fluoro-3-methyl-1H-indol-7-yl]-N-[(4,5-dichloro-2-thienyl)sulfonyl]-2-propenamide (DG-041), a Potent and Selective Prostanoid EP3 Receptor Antagonist, as a Novel Antiplatelet Agent That Does Not Prolong Bleeding
Singh, Jasbir
Zeller, Wayne
Zhou, Nian
Hategan, Georgeta
Mishra, Rama K.
Polozov, Alex
Yu, Peng
Onua, Emmanuel
Zhang, Jun
Ramirez, Jose L.
Sigthorsson, Gudmundur
Thorsteinnsdottir, Margret
Kiselyov, Alex. S.
Zembower, David E.
Andresson, Thorkell
Gurney, Mark E.
JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (01) : 18 - 36
[24] BIS(HETEROARYL)PIPERAZINE (BHAP) REVERSE-TRANSCRIPTASE INHIBITORS - STRUCTURE-ACTIVITY-RELATIONSHIPS OF NOVEL SUBSTITUTED INDOLE ANALOGS AND THE IDENTIFICATION OF 1-[(5-METHANESULFONAMIDO-1H-INDOL-2-YL)-CARBONYL]-4-[3-[(1-METHYLETHYL)AMINO]-PYRIDINYL]PIPERAZINE MONOMETHANESULFONATE (U-90152S), A 2ND-GENERATION CLINICAL CANDIDATE
ROMERO, DL
MORGE, RA
GENIN, MJ
BILES, C
BUSSO, M
RESNICK, L
ALTHAUS, IW
REUSSER, F
THOMAS, RC
TARPLEY, WG
JOURNAL OF MEDICINAL CHEMISTRY, 1993, 36 (10) : 1505 - 1508

← 1 2 3 →